Creatine Safety & Tolerability in Huntington's Disease

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital

Criteria

Inclusion Criteria:

• Individuals who have completed the CREST-UP1 study.

• Individuals who are able to take oral medication.

• Individuals capable of providing informed consent and complying with trial procedures.

Exclusion Criteria:

• History of known sensitivity or intolerability to creatine.

• Clinical evidence of unstable medical illness in the investigator's judgment.

Additional eligibility criteria apply.